{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:11:52Z","timestamp":1787026312192,"version":"build-2736575974"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T00:00:00Z","timestamp":1644278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Despite the advances in the control of traditional risk factors, coronary artery disease (CAD) remains the greatest cause of morbidity and mortality. Our aim was to establish the relation between plasma proteomics analysis and the risk of cardiovascular events in patients with stable CAD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>Patients with stable CAD and documented coronary atherosclerosis were screened for inclusion. Using proximity extension assays, 177 plasma proteins were simultaneously measured. The endpoint consisted of the first major adverse cardiovascular event (MACE) and was the composite of cardiovascular death, acute coronary syndrome, stroke, transient ischemic attack, or acute limb ischemia at 18 months follow-up. Cox proportional-hazards regression with adjustment for multiple comparisons was used to identify biomarkers for the outcomes of interest.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The cohort consisted of 229 patients. Six mediators were associated with MACE (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001). For these markers, the risk of MACE was calculated: tumor necrosis factor receptor superfamily member 13B (HR = 1.65; 95% CI: 1.30\u20132.10), C-C motif chemokine-3 (HR = 1.57; 95% CI: 1.23\u20131.98), decorin (HR = 1.65; 95% CI: 1.26\u20132.16), fibroblast growth factor-23 (HR = 1.56; 95% CI: 1.23\u20131.99), tumor necrosis factor-related apoptosis-inducing ligand-receptor 2 (TRAIL-R2) (HR = 1.61; 95% CI: 1.23\u20132.11), and tumor necrosis factor receptor superfamily member 10A (HR = 1.69; 95% CI: 1.25\u20132.29). Except for TRAIL-R2, the other proteins were associated with MACE independent of age, sex, diabetes mellitus, or estimated glomerular filtration rate.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with stable CAD, five novel biomarkers were identified as independent risk factors for adverse outcomes. Novel biomarkers could represent pharmacological targets for the prevention of adverse cardiovascular events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2022.731325","type":"journal-article","created":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T02:43:13Z","timestamp":1644288193000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Relation Between Plasma Proteomics Analysis and Major Adverse Cardiovascular Events in Patients With Stable Coronary Artery Disease"],"prefix":"10.3389","volume":"9","author":[{"given":"Mihaela Ioana","family":"Dregoesc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian Bogdan","family":"\u0162igu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siroon","family":"Bekkering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte D. C. C.","family":"van der Heijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorana Daniela","family":"Bolboac\u01ce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo A. B.","family":"Joosten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank L. J.","family":"Visseren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihai G.","family":"Netea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels P.","family":"Riksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian Corneliu","family":"Iancu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1161\/hc0902.104353","article-title":"Inflammation and atherosclerosis","volume":"105","author":"Libby","year":"2002","journal-title":"Circulation."},{"key":"B2","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJM200003233421202","article-title":"C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women","volume":"342","author":"Ridker","year":"2000","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.ahj.2007.02.027","article-title":"Prediction of first coronary events with the Framingham score: a systematic review","volume":"153","author":"Eichler","year":"2007","journal-title":"Am Heart J."},{"key":"B7","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.jacc.2017.06.030","article-title":"Biomarker-based risk model to predict cardiovascular mortality in patients with stable coronary disease","volume":"70","author":"Lindholm","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2016.02.012","article-title":"High-sensitivity Troponin T in relation to coronary plaque characteristics in patients with stable coronary artery disease; results of the ATHEROREMO-IVUS study","volume":"247","author":"Oemrawsingh","year":"2016","journal-title":"Atherosclerosis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.atherosclerosis.2015.04.811","article-title":"HDL cholesterol, leptin and interleukin-6 predict high risk coronary anatomy assessed by CT angiography in patients with stable chest pain","volume":"241","author":"Caselli","year":"2015","journal-title":"Atherosclerosis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ebiom.2018.12.033","article-title":"Predictive value of targeted proteomics for coronary plaque morphology in patients with suspected coronary artery disease","volume":"39","author":"Bom","year":"2019","journal-title":"EBioMedicine."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1093\/eurheartj\/ehaa648","article-title":"Improved cardiovascular risk prediction using targeted plasma proteomic in primary prevention","volume":"41","author":"Hoogeveen","year":"2020","journal-title":"Eur Heart J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J."},{"key":"B13","unstructured":"Definition and Diagnosis of Diabetes Mellitus and Intermediate and Hyperglycaemia"},{"key":"B14","unstructured":"Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e95192","DOI":"10.1371\/journal.pone.0095192","article-title":"Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability","volume":"9","author":"Assarsson","year":"2014","journal-title":"PLoS One."},{"key":"B16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1161\/ATVBAHA.107.155143","article-title":"Death receptors and their ligands in atherosclerosis","volume":"28","author":"Kavurma","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.vph.2014.10.004","article-title":"Tumor necrosis factor-related apoptosis-inducing ligand in vascular inflammation and atherosclerosis: a protector or culprit?","volume":"63","author":"Cheng","year":"2014","journal-title":"Vascul Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/nri2572","article-title":"Cracking the BAFF code","volume":"9","author":"Mackay","year":"2009","journal-title":"Nat Rev Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"542","DOI":"10.4049\/jimmunol.1402070","article-title":"The immunoregulator soluble TACI is released by ADAM10 and reflects B cell activation in autoimmunity","volume":"194","author":"Hoffmann","year":"2015","journal-title":"J Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/nm.3284","article-title":"B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction","volume":"19","author":"Zouggari","year":"2013","journal-title":"Nat Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.117.032790","article-title":"B cell-activating factor neutralization aggravates atherosclerosis","volume":"138","author":"Tsiantoulas","year":"2018","journal-title":"Circulation."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/j.bcp.2007.10.020","article-title":"Expression, regulation and function of trail in atherosclerosis","volume":"75","author":"Kavurma","year":"2008","journal-title":"Biochem Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/1354750X.2018.1539768","article-title":"The temporal pattern of immune and inflammatory proteins prior to a recurrent coronary event in post-acute coronary syndrome patients","volume":"24","author":"Vroegindewey","year":"2019","journal-title":"Biomarkers."},{"key":"B25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1126\/science.7678183","article-title":"Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance","volume":"259","author":"Hotamisligil","year":"1993","journal-title":"Science."},{"key":"B26","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0002-9440(10)65283-2","article-title":"Expression and cellular localization of the CC chemokines PARC and ELC in human atherosclerotic plaques","volume":"154","author":"Reape","year":"1999","journal-title":"Am J Pathol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1161\/01.RES.0000160077.17427.57","article-title":"Platelets and chemokines in atherosclerosis: partners in crime","volume":"96","author":"Weber","year":"2005","journal-title":"Circ Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1161\/ATVBAHA.112.300857","article-title":"Leukocyte-specific CCL3 deficiency inhibits atherosclerotic lesion development by affecting neutrophil accumulation","volume":"33","author":"de Jager","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e45804","DOI":"10.1371\/journal.pone.0045804","article-title":"Chemokines CCL3\/MIP1\u03b1, CCL5\/RANTES and CCL18\/PARC are independent risk predictors of short-term mortality in patients with acute coronary syndromes","volume":"7","author":"de Jager","year":"2012","journal-title":"PLoS ONE."},{"key":"B30","doi-asserted-by":"publisher","first-page":"365","DOI":"10.23750\/abm.v89i3.6024","article-title":"Could decorin be a biomarker of coronary artery disease? A pilot study in human beings","volume":"89","author":"Nazemi","year":"2018","journal-title":"Acta Biomed."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1161\/01.ATV.0000147029.63303.28","article-title":"Decorin promotes aortic smooth muscle cell calcification and colocalizes to calcified regions in human atherosclerotic lesions","volume":"24","author":"Fischer","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1054-8807(97)00001-X","article-title":"Differences in the distribution of versican, decorin, and biglycan in atherosclerotic human coronary arteries","volume":"6","author":"Gutierrez","year":"1997","journal-title":"Cardiovasc Pathol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.atherosclerosis.2005.08.023","article-title":"Decorin overexpression reduces atherosclerosis development in apolipoprotein E-deficient mice","volume":"187","author":"Al Haj Zen","year":"2006","journal-title":"Atherosclerosis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1161\/01.ATV.0000034021.92658.4C","article-title":"Differential accumulation of proteoglycans and hyaluronan in culprit lesions: insights into plaque erosion","volume":"22","author":"Kolodgie","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.matbio.2015.01.023","article-title":"Pivotal role for decorin in angiogenesis","volume":"43","author":"J\u00e4rvel\u00e4inen","year":"2015","journal-title":"Matrix Biol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1038\/ki.2009.405","article-title":"Clinical relevance of FGF-23 in chronic kidney disease","volume":"114","author":"Seiler","year":"2009","journal-title":"Kidney Int Suppl."},{"key":"B37","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1681\/ASN.2013050465","article-title":"Fibroblast growth factor-23 and cardiovascular events in CKD","volume":"25","author":"Scialla","year":"2014","journal-title":"J Am Soc Nephrol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1001\/jamacardio.2018.0653","article-title":"Association of fibroblast growth factor 23 with recurrent cardiovascular events in patients after an acute coronary syndrome: a secondary analysis of a randomized clinical trial","volume":"3","author":"Bergmark","year":"2018","journal-title":"JAMA Cardiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e95402","DOI":"10.1371\/journal.pone.0095402","article-title":"Coexistence of low vitamin D and high fibroblast growth factor-23 plasma levels predicts an adverse outcome in patients with coronary artery disease","volume":"9","author":"Tu\u00f1\u00f3n","year":"2014","journal-title":"PLoS One."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"key":"B41","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fcvm.2019.00016","article-title":"Targeting residual inflammatory risk: a shifting paradigm for atherosclerotic disease","volume":"6","author":"Aday","year":"2019","journal-title":"Front Cardiovasc Med."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.731325\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T02:43:17Z","timestamp":1644288197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.731325\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,8]]},"references-count":41,"alternative-id":["10.3389\/fcvm.2022.731325"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.731325","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,8]]},"article-number":"731325"}}